Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1953 3
1955 2
1956 3
1958 1
1960 2
1961 1
1962 2
1963 1
1966 2
1967 1
1968 3
1969 1
1970 1
1971 4
1972 4
1973 9
1974 9
1975 4
1976 11
1977 11
1978 11
1979 11
1980 10
1981 11
1982 9
1983 11
1984 12
1985 10
1986 14
1987 23
1988 25
1989 24
1990 13
1991 43
1992 40
1993 38
1994 41
1995 47
1996 43
1997 60
1998 66
1999 71
2000 85
2001 73
2002 94
2003 152
2004 145
2005 185
2006 219
2007 266
2008 238
2009 296
2010 337
2011 332
2012 378
2013 392
2014 419
2015 489
2016 553
2017 569
2018 623
2019 656
2020 697
2021 858
2022 919
2023 837
2024 908
2025 637

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,763 results

Results by year

Filters applied: . Clear all
Page 1
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, McJannett MM, Stockler MR, Violet JA, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Hofman MS, et al. Among authors: lin p. Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11. Lancet. 2021. PMID: 33581798 Clinical Trial.
Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns.
Levin A, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, Herrington WG, Hill G, Inker LA, Kazancıoğlu R, Lamb E, Lin P, Madero M, McIntyre N, Morrow K, Roberts G, Sabanayagam D, Schaeffner E, Shlipak M, Shroff R, Tangri N, Thanachayanont T, Ulasi I, Wong G, Yang CW, Zhang L, Robinson KA, Wilson L, Wilson RF, Kasiske BL, Cheung M, Earley A, Stevens PE. Levin A, et al. Among authors: lin p. Kidney Int. 2024 Apr;105(4):684-701. doi: 10.1016/j.kint.2023.10.016. Kidney Int. 2024. PMID: 38519239 Free article.
Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms.
Sy CL, Chen PY, Cheng CW, Huang LJ, Wang CH, Chang TH, Chang YC, Chang CJ, Hii IM, Hsu YL, Hu YL, Hung PL, Kuo CY, Lin PC, Liu PY, Lo CL, Lo SH, Ting PJ, Tseng CF, Wang HW, Yang CH, Lee SS, Chen YS, Liu YC, Wang FD. Sy CL, et al. Among authors: lin pc. J Microbiol Immunol Infect. 2022 Jun;55(3):359-386. doi: 10.1016/j.jmii.2022.02.001. Epub 2022 Mar 16. J Microbiol Immunol Infect. 2022. PMID: 35370082 Free article. Review.
Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease.
Mielke MM, Anderson M, Ashford JW, Jeromin A, Lin PJ, Rosen A, Tyrone J, Vandevrede L, Willis DR, Hansson O, Khachaturian AS, Schindler SE, Weiss J, Batrla R, Bozeat S, Dwyer JR, Holzapfel D, Jones DR, Murray JF, Partrick KA, Scholler E, Vradenburg G, Young D, Braunstein JB, Burnham SC, de Oliveira FF, Hu YH, Mattke S, Merali Z, Monane M, Sabbagh MN, Shobin E, Weiner M, Udeh-Momoh CT. Mielke MM, et al. Among authors: lin pj. Alzheimers Dement. 2024 Nov;20(11):8216-8224. doi: 10.1002/alz.14184. Epub 2024 Oct 1. Alzheimers Dement. 2024. PMID: 39351838 Free PMC article. Review.
CRISPR-Cas-mediated diagnostics.
Li L, Shen G, Wu M, Jiang J, Xia Q, Lin P. Li L, et al. Among authors: lin p. Trends Biotechnol. 2022 Nov;40(11):1326-1345. doi: 10.1016/j.tibtech.2022.04.006. Epub 2022 May 17. Trends Biotechnol. 2022. PMID: 35595574 Review.
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial.
Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, Mohanty V, Dede M, Nieto Y, Uprety N, Acharya S, Liu E, Wilson J, Banerjee P, Macapinlac HA, Ganesh C, Thall PF, Bassett R, Ammari M, Rao S, Cao K, Shanley M, Kaplan M, Hosing C, Kebriaei P, Nastoupil LJ, Flowers CR, Moseley SM, Lin P, Ang S, Popat UR, Qazilbash MH, Champlin RE, Chen K, Shpall EJ, Rezvani K. Marin D, et al. Among authors: lin p. Nat Med. 2024 Mar;30(3):772-784. doi: 10.1038/s41591-023-02785-8. Epub 2024 Jan 18. Nat Med. 2024. PMID: 38238616 Free PMC article. Clinical Trial.
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
Cancer Genome Atlas Research Network; Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O'Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenberg SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhim R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fenn… See abstract for full author list ➔ Cancer Genome Atlas Research Network, et al. Among authors: lin p. N Engl J Med. 2015 Jun 25;372(26):2481-98. doi: 10.1056/NEJMoa1402121. Epub 2015 Jun 10. N Engl J Med. 2015. PMID: 26061751 Free PMC article.
Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial.
Emmett L, Subramaniam S, Crumbaker M, Joshua AM, Sandhu S, Nguyen A, Weickhardt A, Lee ST, Ng S, Francis RJ, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Gedye C, Rutherford NK, Kumar ASR, Pook D, Ramdave S, Nadebaum DP, Voskoboynik M, Redfern AD, Macdonald W, Krieger L, Schembri G, Chua W, Lin P, Horvath L, Bastick P, Butler P, Zhang AY, McJannett M, Thomas H, Langford A, Hofman MS, Martin AJ, Davis ID, Stockler MR; ENZA-p Trial Investigators; Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Emmett L, et al. Among authors: lin p. Lancet Oncol. 2025 Mar;26(3):291-299. doi: 10.1016/S1470-2045(25)00009-9. Epub 2025 Feb 13. Lancet Oncol. 2025. PMID: 39956124 Clinical Trial.
10,763 results
You have reached the last available page of results. Please see the User Guide for more information.